ChemT Biotech is proud to become a member of Lilly TuneLab™, Eli Lilly’s AI/ML-enabled innovation platform designed to support companies with access to advanced predictive models for drug discovery and development. This partnership aligns closely with ChemT’s mission to build CelMo™, our AI-driven “Virtual Cell” platform that understands and predicts cell behavior, with downstream capabilities including AI agents for cell engineering and de novo small-molecule solutions for cell modulation toward efficient, scalable biomanufacturing.

By combining external AI innovation ecosystems such as TuneLab with ChemT’s own cellular-control engine, we aim to accelerate the discovery of next-generation small molecules for biomanufacturing across multiple cell types. For ChemT, being a member of Lilly TuneLab™ represents another step toward building a new paradigm where AI can help make advanced medicines faster, more scalable, and more accessible. This collaboration strengthens our mission to transform biomanufacturing through AI-driven cellular modulation, leveraging Eli Lilly’s powerful AI/ML platforms built on decades of clinical data.